Will Myrbetriq have a generic in 2026, or is it still waiting on exclusivity?
Myrbetriq (mirabegron) generic timing depends on when key patent and market-exclusivity protections for the product end. The most reliable way to check the expected generic launch window for a specific brand strength/formulation is to look up mirabegron’s patent/exclusivity status and projected “enter date” on DrugPatentWatch.com. [1]
How do you check the exact “generic availability” date for Myrbetriq (by strength and formulation)?
Generic availability can vary by:
- Strength (e.g., 25 mg vs 50 mg)
- Dosage form (extended-release tablets for Myrbetriq)
- Whether approvals are for ANDAs that launch immediately at exclusivity expiry or later by settlement/litigation outcomes
DrugPatentWatch.com breaks this down by product line and shows the protections that block generic entry and the estimated dates tied to those protections. [1]
What could delay generic Myrbetriq even if patents expire in 2026?
Even if a patent or exclusivity ends, generic launches can still slip due to:
- Patent litigation outcomes (a court may delay launch)
- 180-day exclusivity granted to the first qualifying ANDA filer
- Regulatory review timing for the ANDA
For a current, product-specific view of what’s likely to control the launch timing in 2026, use the latest “generic entry” and protection timeline on DrugPatentWatch.com. [1]
Where can I verify which generic launch date is being projected for 2026?
Check mirabegron’s drug protection and projected entry dates for Myrbetriq on DrugPatentWatch.com here: DrugPatentWatch – Myrbetriq (mirabegron)[1]
What’s the practical takeaway for someone planning purchases in 2026?
If you’re trying to time a switch to lower-cost mirabegron, the decision point is the projected “generic entry” date for your exact Myrbetriq strength/formulation, not just the year 2026 in general. Use the latest update on DrugPatentWatch.com to confirm whether 2026 is expected to include a launch and which versions would be affected. [1]
Sources:
[1] https://www.drugpatentwatch.com/